Prognostic value of combined target-organ damage in patients with essential hypertension

American Journal of Hypertension

Volumn 28, Issue 1, 2015, Pages 127-134

  Carpinella, Gerardo ^a   Pagano, Gennaro ^a   Buono, Francesco ^a   Petitto, Marta ^a   Guarino, Giovanna ^a   Orefice, Giuseppe ^a   Rengo, Giuseppe ^a   Trimarco, Bruno ^a   Morisco, Carmine ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Blood pressure; Cardiovascular risk; Chronic kidney disease; Essential hypertension; Hypertension; Left ventricular hypertrophy; Myocardial infarction; Stroke

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; ECHOCARDIOGRAPHY; ECHOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SAMPLE SIZE; TARGET ORGAN DAMAGE; AGE; BLOOD PRESSURE; CHI SQUARE DISTRIBUTION; DISEASE FREE SURVIVAL; GLOMERULUS FILTRATION RATE; HEART RATE; HYPERTROPHY, LEFT VENTRICULAR; ITALY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PREVALENCE; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; SEX DIFFERENCE; TIME;

ANTIHYPERTENSIVE AGENT;

ADULT; AGE FACTORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; GLOMERULAR FILTRATION RATE; HEART RATE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; ITALY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 84922386979     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpu098     Document Type: Article

References (34)

1. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35:580-586.
2. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000; 35:898-903.
3. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116:85-97.
4. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS. Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients. J Am Soc Nephrol 2004; 15:1029-1037.
5. Khan NA, Ma I, Thompson CR, Humphries K, Salem DN, Sarnak MJ, Levin A. Kidney function and mortality among patients with left ventricular systolic dysfunction. J Am Soc Nephrol 2006; 17:244-253.
6. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlof B, Gerdts E, Wright JT Jr, Papademetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H, Devereux RB. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J 2002; 143:319-326.
7. Nardi E, Palermo A, Mule G, Cusimano P, Cottone S, Cerasola G. Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease. J Hypertens 2009; 27:633-641.
8. Foguet Q, Rodriguez A, Saez M, Ubieto A, Beltran M, Barcelo MA, Coll G; VAMPAHICA Study Group. Usefulness of optic fundus examination with retinography in initial evaluation of hypertensive patients. Am J Hypertens 2008; 21:400-405.
9. Tsioufis C, Vezali E, Tsiachris D, Dimitriadis K, Taxiarchou E, Chatzis D, Thomopoulos C, Syrseloudis D, Stefanadi E, Mihas C, Katsi V, Papademetriou V, Stefanadis C. Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study. J Hypertens 2009; 27:744-752.
10. Vernooij JW, van der Graaf Y, Nathoe HM, Bemelmans RH, Visseren FL, Spiering W. Hypertensive target organ damage and the risk for vascular events and all-cause mortality in patients with vascular disease. J Hypertens 2013; 31:492-499.
11. De Luca N, Izzo R, Iaccarino G, Malini PL, Morisco C, Rozza F, Iovino GL, Rao MA, Bodenizza C, Lanni F, Guerrera L, Arcucci O, Trimarco B. The use of a telematic connection for the follow-up of hypertensive patients improves the cardiovascular prognosis. J Hypertens 2005; 23:1417-1423.
12. Buono F, Crispo S, Pagano G, Rengo G, Petitto M, Grieco F, Trimarco B, Morisco C. Determinants of left ventricular hypertrophy in patients with recent diagnosis of essential hypertension. J Hypertens 2014; 32:166-173.
13. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370:1453-1457.
14. Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 2004; 44:84-93.
15. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1-S266.
16. Standards of medical care in diabetes-2006. Diabetes Care 2006; 29:S4-S42.
17. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
18. Clinical Guidelines on the identification, evaluation, and treatment of overweight and obesity in adults\-The evidence report. National Institutes of Health. Obes Res 1998; 6:51S-209S.
19. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
20. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58:1072-1083.
21. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
22. De Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20:1251-1260.
23. Crispo, S., De Gennaro, S., Buono, F., Crispo, A., Meccariello, A., Morisco, C., Trimarco, B. Menopause increases the risk of carotid atherosclerosis in essential hypertension. High Blood Press Cardiovasc Prev 2010; 17:31-36.
24. de Simone G, Devereux RB, Maggioni AP, Gorini M, de Divitiis O, Verdecchia P; MAVI (MAssa Ventricolare sinistra nell'Ipertensione) Study Group. Different normalizations for body size and population attributable risk of left ventricular hypertrophy: the MAVI study. Am J Hypertens 2005; 18:1288-1293.
25. Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, Solinas P, Gorini M, Maggioni AP; MAVI (MAssa Ventricolare sinistra nell'Ipertensione) Study Group. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 2001; 38:1829-1835.
26. Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C, Trevano FQ, Grassi G, Zanchetti A, Sega R. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49:40-47.
27. Sullivan JM, Vander Zwaag RV, el-Zeky F, Ramanathan KB, Mirvis DM. Left ventricular hypertrophy: effect on survival. J Am Coll Cardiol 1993; 22:508-513.
28. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994; 90:1786-1793.
29. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
30. Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S; ONTARGET/TRANSCEND Investigators. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation 2009; 120:1380-1389.
31. Budhwani N, Patel S, Dwyer EM Jr. Electrocardiographic diagnosis of left ventricular hypertrophy: the effect of left ventricular wall thickness, size, and mass on the specific criteria for left ventricular hypertrophy. Am Heart J 2005; 149:709-714.
32. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46.
33. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351:1941-1951.
34. Salvetti M1, Muiesan ML, Paini A, Monteduro C, Agabiti-Rosei C, Aggiusti C, Bertacchini F, Stassaldi D, Castellano M, Agabiti-Rosei E. Left ventricular hypertrophy and renal dysfunction during antihypertensive treatment adversely affect cardiovascular prognosis in hypertensive patients. J Hypertens 2012; 30:411-420.